Living

Ebola Bundibugyo vaccine candidates could enter Phase 1 trials as early as July

By Reuters Reuters
A healthcare worker at the Bunia General Referral Hospital following a resurgence of Ebola involving the Bundibugyo strain, a rarer variant of the virus with no approved vaccine currently available, in Bunia, Ituri province of the Democratic Republic of Congo May 21, 2026. REUTERS/Stringer/File Photo
A healthcare worker at the Bunia General Referral Hospital following a resurgence of Ebola involving the Bundibugyo strain, a rarer variant of the virus with no approved vaccine currently available, in Bunia, Ituri province of the Democratic Republic of Congo May 21, 2026. REUTERS/Stringer/File Photo Stringer Reuters

NAIROBI/DAKAR - Lead vaccine candidates developed by Oxford University and Moderna against Ebola Bundibugyo, the deadly virus that has swept through eastern Democratic Republic of Congol, could enter Phase 1 trials as early as July, ⁠with field trials possible within several months, the head of the Coalition for Epidemic Preparedness Innovations, Richard Hatchett, said on Tuesday.

(Reporting by Anait Miridzhanian and Emma Farge; Editing by Alison Williams)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 16, 2026 at 6:29 AM.

Get one year of unlimited digital access for $159.99
#ReadLocal

Only 44¢ per day

SUBSCRIBE NOW